JP2008538583A5 - - Google Patents

Download PDF

Info

Publication number
JP2008538583A5
JP2008538583A5 JP2008507988A JP2008507988A JP2008538583A5 JP 2008538583 A5 JP2008538583 A5 JP 2008538583A5 JP 2008507988 A JP2008507988 A JP 2008507988A JP 2008507988 A JP2008507988 A JP 2008507988A JP 2008538583 A5 JP2008538583 A5 JP 2008538583A5
Authority
JP
Japan
Prior art keywords
composition
subject
hydrogen
apathy
nefiracetam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008507988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008538583A (ja
Filing date
Publication date
Priority claimed from US11/406,158 external-priority patent/US20060241144A1/en
Application filed filed Critical
Publication of JP2008538583A publication Critical patent/JP2008538583A/ja
Publication of JP2008538583A5 publication Critical patent/JP2008538583A5/ja
Withdrawn legal-status Critical Current

Links

JP2008507988A 2005-04-20 2006-04-19 アパシー症候群を治療するための方法 Withdrawn JP2008538583A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67355505P 2005-04-20 2005-04-20
US11/406,158 US20060241144A1 (en) 2005-04-20 2006-04-17 Method for treating apathy syndrome
PCT/US2006/015513 WO2006113937A2 (en) 2005-04-20 2006-04-19 Method for treating apathy syndrome

Publications (2)

Publication Number Publication Date
JP2008538583A JP2008538583A (ja) 2008-10-30
JP2008538583A5 true JP2008538583A5 (https=) 2009-06-04

Family

ID=37115988

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008507988A Withdrawn JP2008538583A (ja) 2005-04-20 2006-04-19 アパシー症候群を治療するための方法

Country Status (4)

Country Link
US (2) US20060241144A1 (https=)
EP (1) EP1874300B1 (https=)
JP (1) JP2008538583A (https=)
WO (1) WO2006113937A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010530900A (ja) * 2007-06-22 2010-09-16 ザ・リサーチ・ファウンデーション・オブ・ステート・ユニバーシティ・オブ・ニューヨーク 中枢神経系活性を有する置換ピロリジン化合物
NO2490685T3 (https=) 2009-10-22 2018-05-12
BR112013020283A2 (pt) * 2011-02-09 2016-07-19 Univ Johns Hopkins "uso de inibidor de proteína de vesícula sináptica 2a (sv2a), valproato, levetiracetam, brivarecetam e seletracetam no tratamento de deficiência cognitiva, bem como composição farmacêutica compreendendo os mesmos"
DE112012002748T5 (de) 2011-10-21 2014-07-31 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
SE1450131A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc DAA-kombinationsbehandling (t.ex. med ABT-072 eller ABT-333)för användning vid behandling av HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN103044307A (zh) * 2013-01-24 2013-04-17 吉林三善恩科技开发有限公司 以2,4-二羟基苯甲酸为前驱体的吡拉西坦药物共晶及其制备方法
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CN106511307B (zh) * 2015-09-11 2018-10-23 重庆润泽医药有限公司 一种（s）-4-羟基-2氧代-1-吡咯烷乙酰胺缓释胶囊及其制备方法
CN106619530A (zh) * 2015-10-27 2017-05-10 重庆润泽医药有限公司 一种左旋奥拉西坦颗粒及其制备方法
CN106890154B (zh) * 2015-12-17 2018-10-23 重庆润泽医药有限公司 一种左旋奥拉西坦泡腾片及其制备方法
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067614C (en) * 1991-05-02 2002-07-30 Eiichi Otomo Agent for improving dementia
US5461157A (en) * 1992-06-19 1995-10-24 Daiichi Pharmaceutical Co., Ltd. Process for preparing pyrrolidinylacetamide derivatives
CA2215846A1 (en) * 1995-03-23 1996-09-26 Tatsuya Terada Anhydrous crystals
KR100417746B1 (ko) * 1995-07-21 2004-05-31 다이이찌 세이야꾸 가부시기가이샤 입상제제의제조방법
US6107330A (en) * 1995-08-07 2000-08-22 Daiichi Pharmaceutical Co., Ltd. Inhibitor for narcotic analgesic dependence/resistance acquisition
JPH0987178A (ja) 1995-09-22 1997-03-31 Toyama Chem Co Ltd 神経成長因子の作用増強剤
AU727482B2 (en) * 1996-10-01 2000-12-14 Daiichi Pharmaceutical Co., Ltd. Mitochondrial membrane stabilizer
EP1020189B1 (en) * 1997-07-15 2004-05-12 Daiichi Pharmaceutical Co., Ltd. Nefiracetam for prevention and treatment of amnesia caused by propofol
AR020115A1 (es) * 1998-08-06 2002-04-10 Daiichi Seiyaku Co Agente terapeutico o preventivo para epilepsias rebeldes y uso del compuesto para la produccion de los mismos
US20040077709A1 (en) * 1999-05-31 2004-04-22 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
US6423739B1 (en) * 2000-02-23 2002-07-23 Daiichi Pharmaceutical Co., Ltd. Method for aiding cerebral recovery following neurodegeneration
US6348489B1 (en) * 2000-04-11 2002-02-19 Daiichi Pharmaceutical Co., Ltd. Method of treating traumatic brain injury and other neuronal disorders
KR100823668B1 (ko) * 2000-12-28 2008-04-21 해밀턴 파마슈티컬스 인코포레이티드 신경성 통증 치료 및 예방약
CA2457982C (en) * 2001-08-22 2009-11-03 Daiichi Pharmaceutical Co., Ltd. Use of nefiracetam for treating neurodegeneration

Similar Documents

Publication Publication Date Title
JP2008538583A5 (https=)
JP6595565B2 (ja) 免疫関連及び炎症性疾患の治療
CN1084618C (zh) 5－羟色胺拮抗剂的新应用
RU2317294C2 (ru) (имидазол-1-илметил)пиридазин в качестве блокатора nmda рецептора
JP5925065B2 (ja) 医薬組成物
JP2008513498A5 (https=)
JP2007145875A5 (https=)
HUP0204526A2 (hu) 2-Oxo-1-pirrolidin-származékok, eljárás előállításukra és alkalmazásuk
JP2006517939A5 (https=)
SI3075726T1 (en) DERIVATIVES OF UREA OR ITS PHARMACOLOGICAL RECRUITABLE SALTS USED AS FORMIL PEPTIDAL RECEPTOR LIKE 1 (FPRL-1) AGONISTS
JP2006509749A5 (https=)
JP2010534647A5 (https=)
JP2006525276A5 (https=)
JP2008513496A5 (https=)
EA200801165A1 (ru) Антагонисты неосновного рецептора-1 меланинконцентрирующего гормона
RU2007120454A (ru) Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3
US20250228838A1 (en) Methods of use of cyclic amide derivatives to treat sigma receptor mediated disorders
US20100099714A1 (en) AMPA and NMDA Receptor Antagonists for Neurodegenerative Diseases
JP2012515763A5 (https=)
MA28111A1 (fr) Derives des
RU2007119390A (ru) Соединения 4-метоксиметил-пирролидин-2-карбоновой кислоты и их производные - ингибиторы вируса гепатита с
JP2004523557A5 (https=)
RU2311408C2 (ru) Производные аминотетралина в качестве антагонистов мускаринового рецептора
JP2010513489A5 (https=)
JP2004529117A5 (https=)